Alzheimer's Disease Trial, Recruiting NCT07651787 Sponsor: University of Oklahoma Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT07651787
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged between 55 and 95 years old.
  • People whose memory or thinking difficulties fall within a specific mild range, as measured by standard cognitive assessment tools (confirm with trial site for exact scores).
  • People with sufficient hearing and vision to take part in the study assessments.
  • People who speak English.
  • People who have evidence of changes to the blood vessels in the brain, confirmed by a brain scan.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with an active brain or nervous system disease such as multiple sclerosis, uncontrolled seizures, or active brain cancer.
  • People who have had a stroke (other than a mini-stroke, known as a TIA) within the 60 days before the first study visit.
  • People who have been diagnosed with a condition called amyloid angiopathy, which affects blood vessels in the brain.
  • People with a major psychiatric condition, such as major depression that is not controlled with medication, or a history of alcohol or drug misuse.
  • People with a neurodegenerative disease such as Parkinson's disease or any form of dementia.
  • People who are currently using a commercial brain stimulation or brain-calming device as part of another research study.
  • People who are currently taking certain dietary supplements thought to benefit brain blood flow, such as NAD or NR supplements, L-citrulline, or urolithin.
  • People with an unstable or poorly controlled medical condition, including uncontrolled diabetes, ongoing heart problems, heart failure, chronic lung disease, or blood pressure that remains above a certain level despite medication.
  • People with any other medical condition or medication that, in the opinion of the study doctor, would make it unsafe or unsuitable for them to complete the study.
  • People with severe sensory difficulties that would interfere with the study assessments.

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Peter Mukli, MD, PhD, Department of Neurosurgery, University of Oklahoma Health Campus, Oklahoma, USA

Phone: +1 (405) 271-8001

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Oklahoma
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in cortical neurovascular coupling

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov